| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
18.02.2025 07:25:28
|
Regeneron & Sanofi : FDA Accepts Dupixent SBLA For Priority Review In Bullous Pemphigoid Treatment
(RTTNews) - The U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application or sBLA for Dupixent (dupilumab) to treat adults with bullous pemphigoid, Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF, SNY) said in a statement.
Bullous pemphigoid is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions.
If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S.; The FDA decision is expected by June 20, 2025.
The priority review is granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo.
Priority Review is granted to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions. Dupixent was previously granted Orphan Drug Designation by the FDA for Bullous pemphigoid, which applies to investigational medicines intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S.
Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and chronic obstructive pulmonary disease in different age population.
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.
In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus.
REGN closed Friday's regular trading at 673.60 down $0.67 or 0.10%.
For More Such Health News, visit rttnews.com.
Nachrichten zu Sanofi S.A.
|
25.03.25 |
EURO STOXX 50-Wert Sanofi-Aktie: So viel Gewinn hätte eine Sanofi-Investition von vor 10 Jahren eingebracht (finanzen.ch) | |
|
20.03.25 |
Sanofi-Aktie tiefer: Sanofi stärkt Immunologie-Sparte mit neuer Übernahme (Dow Jones) | |
|
18.03.25 |
EURO STOXX 50-Papier Sanofi-Aktie: So viel Gewinn hätte ein Investment in Sanofi von vor 5 Jahren eingefahren (finanzen.ch) | |
|
11.03.25 |
EURO STOXX 50-Titel Sanofi-Aktie: So viel hätte eine Investition in Sanofi von vor 3 Jahren abgeworfen (finanzen.ch) | |
|
04.03.25 |
EURO STOXX 50-Titel Sanofi-Aktie: So viel Gewinn hätte eine Sanofi-Investition von vor einem Jahr eingebracht (finanzen.ch) | |
|
03.03.25 |
Kühne+Nagel-Aktie: Zusammenarbeit mit Sanofi in der Türkei (AWP) | |
|
28.02.25 |
Sanofi-Aktie: Was Analysten von Sanofi erwarten (finanzen.net) | |
|
25.02.25 |
EURO STOXX 50-Titel Sanofi-Aktie: So viel hätten Anleger an einem Sanofi-Investment von vor 10 Jahren verdient (finanzen.ch) |